Genesoft Factive review
Anti-Infectives Drugs Advisory Committee will review Genesoft's Factive (gemifloxacin) for community-acquired pneumonia and acute exacerbation of chronic bronchitis at its March 4 meeting. Factive received a "not approvable" letter from FDA in December 2000 under an application sponsored by SmithKline Beecham. Following its merger with Glaxo, GSK returned rights for Factive to LG Life Sciences, which then licensed the drug to South San Francisco-based Genesoft. The meetings will be held at the Marriott Washingtonian Center in Gaithersburg, Md. beginning at 8 a.m. on March 4 and 9 a.m. on March 5...
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.